Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis
Gravallese EM, Schett G (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 14
Pages Range: 631-640
Journal Issue: 11
DOI: 10.1038/s41584-018-0091-8
Abstract
Over the past several years, a pathophysiological role for the IL-23-IL-17 pathway in human disease has been defined. A subset of rheumatic diseases, including psoriatic arthritis (PsA) and ankylosing spondylitis (AS), are now acknowledged to be triggered by dysregulated IL-23-IL-17 pathway activation. Genetic evidence links the IL-23-IL-17 pathway to inflammation in these rheumatic diseases, and mechanistic data from mice support a functional role for IL-23-IL-17 pathway activation in the development of enthesitis and in entheseal bone formation. Furthermore, analysis of human tissue samples, as well as data from clinical trials, also supports a role for activation of the IL-23-IL-17 pathway in these diseases. The unique bone phenotype that occurs in PsA and AS is a surprising coexistence of both systemic bone loss and periosteal and entheseal bone formation and is likely to be the result of the actions of IL-23 and/or IL-17 on bone. However, the effects of these cytokines on bone cells are complex, and controversy remains regarding their exact roles in the specific bone microenvironments relevant to PsA and AS.
Authors with CRIS profile
Involved external institutions
United States (USA) (US)How to cite
APA:
Gravallese, E.M., & Schett, G. (2018). Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nature Reviews Rheumatology, 14(11), 631-640. https://doi.org/10.1038/s41584-018-0091-8
MLA:
Gravallese, Ellen M., and Georg Schett. "Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis." Nature Reviews Rheumatology 14.11 (2018): 631-640.
BibTeX: Download